This trial is active, not recruiting.

Condition retinal vein occlusion
Sponsor Johns Hopkins University
Start date January 2013
End date December 2020
Trial size 115 participants
Trial identifier NCT01875770, CAPTURE


This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Treated with Ranibizumab in previous trial

Primary Outcomes

Mean change from baseline in BCVA at 5 and 10 years.
time frame: 10 years

Secondary Outcomes

Mean change from baseline in foveal thickness at 5 and 10 years
time frame: 10 years

Eligibility Criteria

Male or female participants from 18 years up to 99 years old.

Inclusion Criteria: - All patients who have been enrolled in the following three trials will be included in the study: A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)" Exclusion Criteria:

Additional Information

Official title Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Principal investigator Peter Campochiaro, MD
Description People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Johns Hopkins University.